PCSK9 and myocardial infarction: Early PCSK9 inhibitor therapy significantly reduces the risk of major adverse cardiovascular events, including nonfatal myocardial infarction, cardiogenic death, stroke, hospitalization for recurrent ACS, and coronary revascularization.